A Multicentre, Randomised, Double-blind, Placebo-controlled, Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 17 Mar 2026
At a glance
- Drugs TDI 01 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Tide Pharmaceutical
Most Recent Events
- 17 Mar 2026 New trial record